61 terminated. 61 Phase 2, 18 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 61 | Terminated 61 |
| Phase 1 | 18 | Terminated 18 |
| Phase 3 | 3 | Terminated 3 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B BE-101 - Hemophilia B, Hemophilia B, Moderately Severe or Severe | Phase 1 / Phase 2 | Terminated | Be Biopharma | 5 | 2024-12-04 | 2026-06-15 |
| A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia VLX-1005, Placebo - Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia | Phase 2 | Terminated | Veralox Therapeutics | 24 | 2023-09-26 | 2025-11-25 |
| A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors SerpinPC - Hemophilia B with Inhibitor, Hemophilia B | Phase 2 | Terminated | ApcinteX Ltd | 3 | 2023-07-28 | 2025-03-11 |
| The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B SerpinPC - Hemophilia a, Hemophilia B | Phase 2 | Terminated | ApcinteX Ltd | 60 | 2023-07-06 | 2025-03-11 |
| Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2023-03-10 | 2025-12-05 |
| Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia PF-06835375 - Primary Immune Thrombocytopenia | Phase 2 | Terminated | Pfizer | 61 | 2022-02-02 | 2026-10-16 |
| Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders Iptacopan - Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD) | Phase 2 | Terminated | Novartis Pharmaceuticals | 19 | 2021-12-21 | 2025-10-16 |
| Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B verbrinacogene setparvovec - Hemophilia B | Phase 1 / Phase 2 | Terminated | Spur Therapeutics | 6 | 2021-12-06 | 2026-07-31 |
| Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis Rituximab, Infliximab, Tocilizumab - Giant Cell Arteritis, Takayasu Arteritis | Phase 2 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 22 | 2021-07-14 | 2025-06-17 |
| Antithrombin III in Infectious Disease Caused by COVID-19 Antithrombin III - Antithrombin III Deficiency, Covid19 | Phase 2 | Terminated | Enrique Ginzburg | 52 | 2021-07-06 | 2022-09-07 |
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Coagulation Factor VIIa variant - Factor VII Deficiency, Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Terminated | Catalyst Biosciences | 19 | 2021-05-17 | 2021-12-21 |
| Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A SIG-001 - Hemophilia A | Phase 1 / Phase 2 | Terminated | Eli Lilly and Company | 3 | 2020-09-28 | 2024-09-04 |
| Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19 Bemiparin - Covid-19 | Phase 2 | Terminated | Fundación de investigación HM | 81 | 2020-06-04 | 2022-06-07 |
| A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects SHP648 - Hemophilia B | Phase 1 / Phase 2 | Terminated | Baxalta now part of Shire | 2 | 2020-05-13 | 2022-05-19 |
| ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery Fibrinogen Concentrate Human, Prothrombin Complex Concentrate, Fresh Frozen Plasma - Bleeding, Cardiac Defect | Phase 2 | Terminated | IRCCS Policlinico S. Donato | 40 | 2020-02-27 | 2021-11-03 |
| Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A OCTA101 - Severe Hemophilia A | Phase 1 / Phase 2 | Terminated | Octapharma | 36 | 2019-07-03 | 2026-10-15 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 12 | 2019-02-20 | 2026-04-24 |
| Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients Biological: M254, Placebo, Intravenous immunoglobulin (IVIg) - Immune Thrombocytopenic Purpura (ITP) | Phase 1 / Phase 2 | Terminated | Momenta Pharmaceuticals, Inc. | 50 | 2018-12-21 | 2025-05-28 |
| Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors Befovacimab (BAY1093884) - Hemophilia A and B | Phase 2 | Terminated | Bayer | 24 | 2018-07-24 | 2020-11-30 |
| A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy FLT180a - Hemophilia B | Phase 1 / Phase 2 | Terminated | Spur Therapeutics | 10 | 2018-07-10 | 2023-07-20 |
Showing 20 of 61. Sign in to see all of them.
Hemophilia A (12) · Hemophilia B (12) · Thrombocythemia, Essential (12) · Myeloproliferative Disorders (11) · Polycythemia Vera (11) · Purpura, Thrombocytopenic, Idiopathic (11) · Primary Myelofibrosis (10) · Thrombocytopenia (7) · Hematologic Diseases (6) · Purpura, Thrombotic Thrombocytopenic (5) · Blood Platelet Disorders (4) · Leukemia (4) · Leukemia, Myeloid, Acute (4) · Myelodysplastic Syndromes (4)
Hemic and Lymphatic Diseases (61) · Hematologic Diseases (55) · Hemorrhagic Disorders (50) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (32) · Blood Coagulation Disorders, Inherited (28) · Blood Platelet Disorders (28) · Genetic Diseases, Inborn (27) · Pathologic Processes (26) · Pathological Conditions, Signs and Symptoms (26) · Coagulation Protein Disorders (22) · Immune System Diseases (18) · Cytopenia (17) · Hemorrhage (16) · Signs and Symptoms (16)
Cyclophosphamide (5) · fludarabine phosphate (5) · Cyclosporine (3) · Whole-Body Irradiation (3) · ruxolitinib (3) · Adrenal Cortex Hormones (2) · Antilymphocyte Serum (2) · Busulfan (2) · Methylprednisolone (2) · Peripheral Blood Stem Cell Transplantation (2) · Protein C (2) · Radiotherapy (2) · Rituximab (2) · Staphylococcal Protein A (2) · Stem Cell Transplantation (2)
ApcinteX Ltd (2) · Bayer (2) · Mayo Clinic (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Pfizer (2) · Protalex, Inc. (2) · Shionogi (2) · Spur Therapeutics (2) · Archemix Corp. (1) · Assistance Publique - Hôpitaux de Paris (1) · Avigen (1) · Baxalta now part of Shire (1) · Baylor College of Medicine (1) · Be Biopharma (1) · BioMarin Pharmaceutical (1)
United States (42) · United Kingdom (18) · Italy (13) · Canada (9) · France (9) · Spain (9) · Australia (7) · Germany (5) · Taiwan (5) · Turkey (Türkiye) (5) · Belgium (4) · India (4) · Poland (4) · Austria (3) · Bulgaria (3)
Ruben A. Mesa, MD (2) · Albert Assad, MD (1) · Andrea Kelleher, MBBS (1) · Antonio Cubillo, MD (1) · Bahman Guyuron, MD (1) · Bertrand Godeau, Professor (1) · Bipin N. Savani, MD (1) · Colleen Delaney, MD, MSC (1) · Craig Kessler, MD (1) · Craig Seaman, MD, MS (1) · David Jayne (1) · Elisabeth Sonesson, PhD (1)
PMID 35857660, PMID 18463354, PMID 20059562, PMID 23014711, PMID 23829485, PMID 25459642, PMID 26224646, PMID 27515248, PMID 28622623, PMID 30488420, PMID 35244208, PMID 36408876, PMID 39911044, PMID 40197980, PMID 40239068, PMID 40750723, PMID 41366634, PMID 41734390
2017 (2), 2018 (2), P30CA015083 (2), 2014 (1), 2015 (1), 2016 (1), 2023 (1), T32CA009515 (1)